(Q33401816)

English

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

H L Kindler

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D A Richards

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L E Garbo

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E B Garon

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J J Stephenson

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C M Rocha-Lima

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Safran

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Chan

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D M Kocs

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Galimi

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J McGreivy

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S L Bray

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Hei

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E G Feigal

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Loh

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C S Fuchs

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

13 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2834-2842

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Igf1r as a therapeutic target in a mouse model of basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Randomized phase II trials: a long-term investment with promising returns

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS142

21 January 2018

Identifiers

10.1093/ANNONC/MDS142

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401816&oldid=1536389712"